Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
